Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline

CDK4/6 inhibitors HER2-low Pi3Ka inhibitors advanced breast cancer germline BRCA1/2 mutations pathogenic/likely pathogenic variants

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Jun 2023
Historique:
received: 21 04 2023
revised: 20 06 2023
accepted: 21 06 2023
medline: 14 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

We explored the outcomes of germline

Identifiants

pubmed: 37444415
pii: cancers15133305
doi: 10.3390/cancers15133305
pmc: PMC10340438
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Breast Cancer Res Treat. 2022 Nov;196(1):121-128
pubmed: 36070058
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
JAMA Oncol. 2019 Aug 01;5(8):1205-1214
pubmed: 30973611
EMBO Mol Med. 2020 Jun 8;12(6):e11217
pubmed: 32400970
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Nat Rev Drug Discov. 2009 Aug;8(8):627-44
pubmed: 19644473
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Front Oncol. 2019 Aug 13;9:759
pubmed: 31456944
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016
pubmed: 33523233
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
BMC Cancer. 2009 Mar 19;9:86
pubmed: 19298662
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Ann Oncol. 2021 Sep;32(9):1148-1156
pubmed: 34116144
Ann Oncol. 2019 Nov 1;30(11):1842
pubmed: 31407010
Clin Cancer Res. 2022 Apr 14;28(8):1493-1499
pubmed: 35149538
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Cancer Discov. 2012 Nov;2(11):1048-63
pubmed: 22915751
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
PLoS One. 2013 Sep 27;8(9):e75864
pubmed: 24086649
N Engl J Med. 2022 Mar 10;386(10):942-950
pubmed: 35263519
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Br J Cancer. 2021 Mar;124(7):1249-1259
pubmed: 33473169
Clin Cancer Res. 2019 Jul 15;25(14):4363-4374
pubmed: 30914433
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Cancer Discov. 2017 Jul;7(7):675-693
pubmed: 28630051
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Biochim Biophys Acta. 2009 Dec;1796(2):309-14
pubmed: 19683559
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
Cancers (Basel). 2022 Nov 30;14(23):
pubmed: 36497418
Hum Pathol. 2015 Feb;46(2):182-90
pubmed: 25522926
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
JCO Precis Oncol. 2022 Mar;6:e2100140
pubmed: 35235412
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
JAMA Oncol. 2019 Oct 1;5(10):1506-1508
pubmed: 31465090
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
BMC Cancer. 2008 May 30;8:155
pubmed: 18513387
Lancet Oncol. 2021 Apr;22(4):499-511
pubmed: 33676601
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Breast Care (Basel). 2019 Dec;14(6):344-353
pubmed: 31933579
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11866-71
pubmed: 10518542
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
Breast. 2022 Oct;65:145-150
pubmed: 35970028
J Clin Oncol. 2021 Nov 1;39(31):3430-3440
pubmed: 34292776
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47
pubmed: 27402769
Cancer Discov. 2012 Nov;2(11):1036-47
pubmed: 22915752
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
Expert Opin Biol Ther. 2020 Sep;20(9):1009-1024
pubmed: 32255704
Clin Cancer Res. 2017 Jul 1;23(13):3405-3415
pubmed: 28069724
Breast Cancer Res Treat. 2016 Feb;155(3):597-601
pubmed: 26888723
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Oncol Ther. 2021 Dec;9(2):575-589
pubmed: 34308518
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
PLoS Med. 2016 Dec 13;13(12):e1002193
pubmed: 27959926
Nature. 1997 Sep 11;389(6647):187-90
pubmed: 9296497
J Natl Cancer Inst. 2020 Dec 14;112(12):1231-1241
pubmed: 32091585

Auteurs

Marta Nerone (M)

Service of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Lorenzo Rossi (L)

Service of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Rosaria Condorelli (R)

Service of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Vilma Ratti (V)

Service of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Fabio Conforti (F)

Oncology Unit, Humanitas Gavazzeni, 24125 Bergamo, Italy.

Antonella Palazzo (A)

Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.

Rossella Graffeo (R)

Service of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Classifications MeSH